ALX Oncology Holdings Inc. a prominent immuno-oncology firm with specialization in the development of therapies to suppress the CD47 immune checkpoint pathway, has recently embarked on a Phase 2 investigator-sponsored trial (IST). The primary of this study is to investigate the efficacy of a neoadjuvant radiation and evorpacept’an innovative CD47 blocker’when combined with Pembrolizumab (KEYTRUDA) in patients suffering from HPV-Mediated Oropharyngeal Cancer (HPVOC) who have not undergone any previous treatment.
The trial has been initiated to involve patients with early-stage locally advanced, resectable HPVOC. Evorpacept is a next-generation CD47 blocker and its combination with Pembrolizumab, an antibody drug acting against the cellular protein PD-1, could potentially offer a new therapeutic alternative for patients with HPVOC. The CD47-SIRPα ‘do not eat me’ signaling pathway, blocked by evorpacept, has been recognized as a common immune evasion strategy in several cancers.
The open-label, single-arm Phase 2 investigator-sponsored trial is being spearheaded by Dr. Joseph A. Califano III, renowned Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center at the University of California, San Diego. The study has been earmarked as NCT05787639 and will be carried out across multiple centers, emphasizing collaborative efforts to tackle this medical challenge.
This concerted investigation aims at creating a robust body of evidence supporting the effectiveness of this novel therapy. Additionally, it aspires to foster greater understanding of the potential role and impact of combining the CD47 pathway blocker with the anti-PD-1 treatment for specific groups of cancer patients.
As HPV-Mediated Oropharyngeal Cancer is a significant global health issue, the medical community is following this trial with considerable anticipation. The outcome of this trial could potentially chart the course for further research, development, and application of related therapies in the fight against various types of cancer.
Comments